Literature DB >> 803867

The association of the IGA levels of serum and whole saliva with the progression of oral cancer.

A M Brown, E T Lally, A Frankel, R Harwick, L W Davis, C J Rominger.   

Abstract

Elevated IgA concentrations in the serum and whole saliva of patients with neoplastic disease have been reported. However, there does not seem to be any information available on the correlation of the secretory immunoglobulins of these patients with the progress of their disease. The whole saliva and sera of 102 cases of squamous carcinoma of the oral mucosa were studied. Patients were subclassified into age-matched groups of primary untreated cancer (21), recurrent cancer (18), and "cured" patients who had been free of disease for at least 9 months (16). A separate group of laryngeal (14) patients was included. Sixteen (16) patients treated by radiation therapy alone were also included to test the effects of radiation on whole saliva IgA. An age-matched group of patients (17) with moderate to severe periodontal disease served as controls. Unstimulated whole saliva was collected for 15 minutes and stored at 0 degrees C. IgA was quantitated by radial immunodiffusion on Hyland and Meloy Laboratory low level plates with 7S and 11S standards. Serum IgA was measured on Hyland plates with serum standards. Protein content of saliva was assayed by the Lowry method. Flow rate was quantitated for the 15-minute collection period. Primary oral and laryngeal cancer patients had a two-fold increase of serum and salivary IgA compared to controls. Recurrent cancer patients had even greater elevation of salivary IgA. Cured patients showed a persistent elevation of serum but a return to normal of salivary IgA. Radiation therapy did not markedly influence the level of salivary IgA. A followup study of 26 patients confirmed this pattern of a drop in whole salivary IgA with cure and a spike with recurrence. It would appear that IgA levels of whole saliva and serum are elevated in oral cancer patients, and that salivary IgA levels may prove useful in distinguishing patients with possible recurrent disease.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 803867     DOI: 10.1002/1097-0142(197504)35:4<1154::aid-cncr2820350421>3.0.co;2-d

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Increases in immunoglobulin and complement in patients with esophageal or gastric cancer.

Authors:  T Saito; A Kuwahara; T Kinoshita; Y Shigemitsu; K Shimoda; M Miyahara; M Kobayashi
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

2.  Plasma cells and immunoglobulin-synthesis in oral precancer and cancer. Correlation with dysplasia, cancer differentiation, radio- and chemotherapy.

Authors:  T Löning; A Burkhardt
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1979

3.  Serum immunoglobulins in brain tumours.

Authors:  S Manjula; A R Aroor; A Raja; S N Rao; A Rao
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

4.  Mucosal immunodeficiency in smokers, and in patients with epithelial head and neck tumours.

Authors:  J R Barton; M A Riad; M N Gaze; A G Maran; A Ferguson
Journal:  Gut       Date:  1990-04       Impact factor: 23.059

5.  Quantitative immunohistochemistry of immunoglobulin- and J-chain-producing cells in human parotid and submandibular salivary glands.

Authors:  F R Korsrud; P Brandtzaeg
Journal:  Immunology       Date:  1980-02       Impact factor: 7.397

6.  Serum immunoglobulin levels A, G, M, D and TNM classification in breast cancer.

Authors:  M Munzarovà; A Trnka; A Malìr
Journal:  Br J Cancer       Date:  1977-04       Impact factor: 7.640

7.  Salivary secretory immunoglobulin A reactivity: a comparison to cortisol and α-amylase patterns in the same breast cancer survivors.

Authors:  Maude Lambert; Marie-Ève Couture-Lalande; Kelly Brennan; Aldin Basic; Sophie Lebel; Catherine Bielajew
Journal:  Contemp Oncol (Pozn)       Date:  2018-09-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.